Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 17/20 | 0.63 |
| ▸ | CHRM1 | P11229 | 16/20 | 0.63 |
| ▸ | CHRM3 | P20309 | 13/20 | 0.63 |
| ▸ | CHRM4 | P08173 | 11/20 | 0.63 |
| ▸ | CHRM5 | P08912 | 8/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | DRD1 | P21728 | 1/20 | 0.57 |
| ▸ | DRD5 | P21918 | 1/20 | 0.57 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8589270 | 0.79 | LMNA (0.48) | CHRM2CHRM1CHRM3CHRM4CHRM5 | |
| SCHEMBL12648694 | 0.77 | CHRM2 (1.00) | CHRM2CHRM1CHRM3CHRM4CHRM5 | |
| SCHEMBL1933106 | 0.77 | CYP1A2 (0.56) | CHRM2CHRM1CHRM3CHRM4 | |
| SCHEMBL7550095 | 0.73 | CHRM2 (1.00) | CHRM2CHRM1CHRM3CHRM4CHRM5 | |
| SCHEMBL30553076 | 0.73 | CHRM2 (1.00) | CHRM2CHRM1CHRM3CHRM4CHRM5 | |
| SCHEMBL29462268 | 0.73 | CHRM2 (1.00) | CHRM2CHRM1CHRM3CHRM4CHRM5 | |
| SCHEMBL10515842 | 0.72 | CHRM2 (0.98) | CHRM2CHRM1CHRM3CHRM4CHRM5 | |
| SCHEMBL8880703 | 0.71 | CHRM2 (0.59) | CHRM2CHRM1CHRM3CHRM4CHRM5 | |
| SCHEMBL9728077 | 0.71 | CHRM2 (0.77) | CHRM2CHRM1CHRM3CHRM4CHRM5 | |
| SCHEMBL9728152 | 0.69 | CHRM2 (0.77) | CHRM2CHRM1CHRM3CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3324966-A1 | MUSCARINIC COMBINATION OF A SELECTIVE M2-ANTAGONIST AND A PERIPHERAL NON-SELECTIVE ANTAGONIST FOR TREATING HYPOCHOLINERGIC DISORDERS | Chase Pharmaceuticals Corporation (US) | 2018-05-30 | — | — | EP | claimed |
| WO-2017147104-A1 | MUSCARINIC M2-ANTAGONIST COMBINATIONS | CHASE PHARMACEUTICALS CORPORATION (US) | 2017-08-31 | — | — | WO | claimed |
| WO-2017015349-A1 | MUSCARINIC COMBINATION OF A SELECTIVE M2-ANTAGONIST AND A PERIPHERAL NON-SELECTIVE ANTAGONIST FOR TREATING HYPOCHOLINERGIC DISORDERS | CHASE PHARMACEUTICALS CORPORATION (US) | 2017-01-26 | — | — | WO | claimed |
| EP-3324966-A1 | MUSCARINIC COMBINATION OF A SELECTIVE M2-ANTAGONIST AND A PERIPHERAL NON-SELECTIVE ANTAGONIST FOR TREATING HYPOCHOLINERGIC DISORDERS | Chase Pharmaceuticals Corporation (US) | 2018-05-30 | — | — | EP | disclosed |
| WO-2018039159-A1 | MUSCARINIC M2-ANTAGONIST COMBINATION | CHASE PHARMACEUTICALS CORPORATION (US) | 2018-03-01 | — | — | WO | disclosed |
| WO-2017147104-A1 | MUSCARINIC M2-ANTAGONIST COMBINATIONS | CHASE PHARMACEUTICALS CORPORATION (US) | 2017-08-31 | — | — | WO | disclosed |
| WO-2017015349-A1 | MUSCARINIC COMBINATION OF A SELECTIVE M2-ANTAGONIST AND A PERIPHERAL NON-SELECTIVE ANTAGONIST FOR TREATING HYPOCHOLINERGIC DISORDERS | CHASE PHARMACEUTICALS CORPORATION (US) | 2017-01-26 | — | — | WO | disclosed |
| WO-2011069156-A2 | COMPOSITIONS AND METHODS FOR ENHANCING ODORANT RECEPTOR ACTIVITY | DUKE UNIVERSITY (US) | 2011-06-09 | — | — | WO | disclosed |